Navigation Links
Epilepsia Publishes Results From Two Studies Of Eisai's Perampanel
Date:8/20/2012

WOODCLIFF LAKE, N.J., Aug. 20, 2012 /PRNewswire/ -- Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset Seizures: Results of Randomized Global Phase III Study 305," and "Perampanel, A Selective, Non-Competitive AMPA Receptor Antagonist, as Adjunctive Therapy for Refractory Partial-Onset Seizures: Interim Results from Phase III, Open-Label Extension Study 307," were published today in the online publication of  Epilepsia.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO)

The marketing authorization application for perampanel is currently under review with the U.S. Food and Drug Administration.

About Perampanel
Perampanel is an orally administered, selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist, discovered and being developed by Eisai. 

About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business.  Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. 

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com/US.  

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.  Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.  Eisai employs approximately 11,000 employees worldwide. 

 

 

 


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
2. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
3. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
4. Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
5. ShangPharma Announces Second Quarter 2012 Results
6. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
7. Organovo Reports Q2 2012 Financial Results, Provides Business Update
8. ULURU Inc. Reports Second Quarter 2012 Financial Results
9. China Pharma Holdings, Inc. Reports Second Quarter 2012 Financial Results
10. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
11. Nephros Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 EnvoyHealth, a Diplomat company, has ... program for CleverCap LITE, a technology designed to improve ... deliver innovative health technology solutions and services that help ... CleverCap LITE offers medication monitoring and ... cover: Records date ...
(Date:7/26/2017)... 2017 E.I. Medical Imaging (EIMI) has partnered ... custom design the worlds first ultrasound system to be used ... native habitat. In preparation for a piece produced by ... Week, Dr. Guttridge approached EIMI with the idea of an ... hammerhead sharks underwater. ...
(Date:7/26/2017)... YORK , July 26, 2017 The ... Annual Prix Galien USA Award Nominees. ... the Prix Galien Award recognizes outstanding biomedical and technology product ... To qualify, each candidate must be U.S. ... last five years and demonstrate tremendous potential to impact human ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... ... past six years, Lightning Labels has sent out a call for users of its custom ... creativity of their designs. Submissions this year were open from May 18 to July 1 ... winners of the sixth annual Photo Contest, along with the prizes they've received:, ...
(Date:8/22/2017)... ... , ... Five Star Glass is new to the Texas market, but is proudly managed by ... most makes and models, in Grand Prairie, TX, located in the center of the DFW ... family owned business for the past 40 years with 32 convenient locations in Texas, Nevada ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without ... abuse and neglect, and the struggles faced while hoping for a better life. ... published author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins ... Managing Member for t4 Leadership Development & Consulting. He has spent his career ... “success”: physician leadership development, servant leadership, data driven process improvement, and supportive technology. ...
(Date:8/22/2017)... ... 22, 2017 , ... Although Labor Day is not as popular for fireworks ... weekend displays, and numerous households celebrate the unofficial end of summer with backyard fireworks ... pets. , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, ...
Breaking Medicine News(10 mins):